CORRECTION Open Access

## Correction to: Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic



Brandon Brown<sup>1</sup>, Jamie L. Weiss<sup>1</sup>, Scott Kolodny<sup>1</sup>, Xiangyi Meng<sup>1</sup>, Ian M. Williams<sup>2</sup> and John A. Osborne<sup>3\*</sup>

Correction to: BMC Neurol (2019) 19:287 https://doi.org/10.1186/s12883-019-1506-0

Following publication of the original article [1], an error was noted regarding the year found in the paragraph of the Background section.

The sentence should read 'As of 31 August **2019**, it is estimated that more than 293,400 patients have been treated with fingolimod, corresponding to approximately 714,600 patient-years of exposure (data on file, Novartis Pharmaceuticals Corporation)'.

## **Author details**

<sup>1</sup>Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936, USA. <sup>2</sup>Oxford PharmaGenesis, Tubney Warren Barn, Tubney, Oxford OX13 5QJ, UK. <sup>3</sup>State of the Heart Cardiology, Plaza 1, Medical Pkwy. N Suite 103, Dallas, TX 75234, USA.

Published online: 21 December 2019

## Reference

 Brown B, Weiss JL, Kolodny S, Meng X, Williams IM, Osborne JA. Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic. BMC Neurol. 2019;19:287. https://doi.org/10.1186/s12883-019-1506-0.

The original article can be found online at https://doi.org/10.1186/s12883-019-1506-0

Full list of author information is available at the end of the article



<sup>\*</sup> Correspondence: josborne@sothcardiology.com

<sup>&</sup>lt;sup>3</sup>State of the Heart Cardiology, Plaza 1, Medical Pkwy. N Suite 103, Dallas, TX